Patent World; Teva Sued, Shares Rise
noted the remarkable success of generics manufacturer Teva in patent infringement disputes. It seems straightaway that Teva is nearly to live sued again, this fourth dimension yesteryear Japanese society Eisai. Teva plans to brand in addition to sell a generic version of Aricept, used for the handling of Alzheimer's disease. The top dog ingredient of Aricept is donepezil hydrochloride and Eisai has warned that it holds a the U.S.A. patent on the donepezil component division of the drug which is valid until 25 Nov 2010 which it promises to enforce rigorously. Investor reply was predictable, if irrational - Teva's portion cost simply continues to rise.
wonders whether Teva's luck volition move along to last. The society appears to convey a bully knack for dodging the raindrops in addition to assumes that it must convey an extremely deep appreciation of the agency the patent organisation works.
Follow Teva's portion cost here
Another Teva here
Comments
Post a Comment